Sarepta’s gene therapy, initially facing safety concerns and patient deaths, experienced a regulatory rollercoaster. The FDA intervened to halt therapy deliveries for ambulatory patients due to safety issues but recently approved the therapy for this group, marking a significant shift in DMD treatment landscape. This decision offers new hope and opportunities for Duchenne muscular dystrophy patients.
Read more from biospace.com